CANCER drug treatments are under scrutiny as a cause of soaring healthcare and claims costs. Current cancer patients will have to brace for changes.
Home Investments Fine-tuning MediShield Life: From 2022, cancer drug treatments must be in “positive...
- Advertisement -
Most Popular
Commentary: Why Samyang Buldak instant noodles is an US$8 billion tariff-proof brand
The ultra-spicy ramen appeals to young Americans seeking exotic tastes – that means it’s immune to Donald Trump’s tariffs, says Shuli Ren for Bloomberg Opinion....
Commentary: Did anyone really win the Great Eastern-OCBC standoff?
After the delisting vote fell short, two groups of Great Eastern shareholders could be left worse off, says former financial journalist Ven Sreenivasan.
